In cancer immunotherapy, PD-1/PD-L1 blockade activates the PD-1/PD-L1 axis, which serves as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity. This evidence concerns the gene PDCD1 and neoplasm.